Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lillicrap

Showing results (141-150 of 216) with videos related to

Pageof 22
Sort By:
Research and Practice in Thrombosis and Haemostasis|April 24, 2019
Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombusYasuaki Shida, Laura L Swystun, Christine Brown, et al.
Research and Practice in Thrombosis and Haemostasis|June 18, 2020
Hemophilia gene therapy knowledge and perceptions: Results of an international surveyFlora Peyvandi, David Lillicrap, Johnny Mahlangu, et al.
Journal of Thrombosis and Haemostasis : JTH|February 19, 2025
Identification of multiple novel procoagulant plasma ligands for stabilin-2Mary Underwood, Felipe Da Veiga Leprevost, Venkatesha Basrur, et al.
Journal of Thrombosis and Haemostasis : JTH|November 21, 2020
Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A populationKenichi Ogiwara, Laura L Swystun, A Simonne Paine, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assaysFanny Lassalle, Yohann Jourdy, Loubna Jouan, et al.
Stem Cells (Dayton, Ohio)|July 7, 2007
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitorsHideto Matsui, Masaru Shibata, Brian Brown, et al.
Blood|February 22, 2007
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWFPeter J Lenting, Philip G de Groot, Simon F De Meyer, et al.
Blood|July 1, 2004
A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exonsPaula D James, Lee A O'Brien, Carol A Hegadorn, et al.
Blood Advances|January 12, 2022
Novel cysteine substitution p.(Cys1084Tyr) causes variable expressivity of qualitative and quantitative VWF defectsOrla Rawley, Laura L Swystun, Christine Brown, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 3, 2011
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia AHideto Matsui, Carol Hegadorn, Margareth Ozelo, et al.
Pageof 22

Showing results (141-150 of 216) with videos related to

Sort By:
Pageof 22
Research and Practice in Thrombosis and Haemostasis|April 24, 2019
Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombusYasuaki Shida, Laura L Swystun, Christine Brown, et al.
Research and Practice in Thrombosis and Haemostasis|June 18, 2020
Hemophilia gene therapy knowledge and perceptions: Results of an international surveyFlora Peyvandi, David Lillicrap, Johnny Mahlangu, et al.
Journal of Thrombosis and Haemostasis : JTH|February 19, 2025
Identification of multiple novel procoagulant plasma ligands for stabilin-2Mary Underwood, Felipe Da Veiga Leprevost, Venkatesha Basrur, et al.
Journal of Thrombosis and Haemostasis : JTH|November 21, 2020
Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A populationKenichi Ogiwara, Laura L Swystun, A Simonne Paine, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 23, 2020
The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assaysFanny Lassalle, Yohann Jourdy, Loubna Jouan, et al.
Stem Cells (Dayton, Ohio)|July 7, 2007
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitorsHideto Matsui, Masaru Shibata, Brian Brown, et al.
Blood|February 22, 2007
Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWFPeter J Lenting, Philip G de Groot, Simon F De Meyer, et al.
Blood|July 1, 2004
A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exonsPaula D James, Lee A O'Brien, Carol A Hegadorn, et al.
Blood Advances|January 12, 2022
Novel cysteine substitution p.(Cys1084Tyr) causes variable expressivity of qualitative and quantitative VWF defectsOrla Rawley, Laura L Swystun, Christine Brown, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 3, 2011
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia AHideto Matsui, Carol Hegadorn, Margareth Ozelo, et al.
Pageof 22